In clinical trials
Digestive & weight
Amycretin
Evidence
Clinical trials
Class
Dual amylin and GLP-1 receptor agonist
KEY TAKEAWAY
Amycretin is a single molecule designed to activate both the amylin receptor and the GLP-1 receptor. Novo Nordisk is developing it for obesity and type 2 diabetes. Amycretin is not FDA-approved and is being tested in clinical trials, in both injected and oral forms.
Written by the Veylo editorial team · Updated
November 2026
What it is
Dual amylin and GLP-1 receptor agonist
Being studied for
Studied for obesity and type 2 diabetes
Key fact
Amycretin is not FDA-approved and is being tested in clinical trials, in both injected and oral forms.
Route
Injection and oral tablet in trials
Evidence strength
Clinical trials
Amycretin is a single molecule designed to activate both the amylin receptor and the GLP-1 receptor. Novo Nordisk is developing it for obesity and type 2 diabetes.
It combines the effect of GLP-1 on appetite and insulin with the effect of amylin on fullness.
Amycretin is not FDA-approved and is being tested in clinical trials, in both injected and oral forms.
Studied for obesity and type 2 diabetes.
Nausea and vomiting were the most commonly reported effects in early trials.
Amycretin: see PubMed and ClinicalTrials.gov for published studies and registered trials. No FDA drug label exists for the uses described.
Veylo content is educational and not medical advice. Peptides that are not FDA-approved are not approved for the uses described.